α1-Adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice

Hypertension

Volumn 32, Issue 6, 1998, Pages 1044-1048

  Makaritsis, Konstantinos P ^a   Gavras, Haralambos ^a   Du, Yue ^a   Chobanian, Aram V ^a   Brecher, Peter ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Blood pressure; Hypercholesterolemia; Losartan; Mice; Prazosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 2 RECEPTOR; APOLIPOPROTEIN E; CHOLESTEROL; LOSARTAN; N(G) NITROARGININE; PRAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; N(G) NITROARGININE METHYL ESTER; PROPRANOLOL;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HYPERLIPIDEMIA; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; ANIMAL; ARTERIOSCLEROSIS; BLOOD PRESSURE; C57BL MOUSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HYPERCHOLESTEROLEMIA; METABOLISM; PATHOLOGY; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HYPERCHOLESTEROLEMIA; LOSARTAN; MICE; MICE, INBRED C57BL; NG-NITROARGININE METHYL ESTER; PRAZOSIN; PROPRANOLOL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TIME FACTORS;

EID: 0032217174     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.6.1044     Document Type: Article

References (20)

1. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest. 1993;91:1453-1458.
2. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
3. Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters: fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis. 1994;108:61-72.
4. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl 5):S65-S72.
5. Kabour A, Henegar JR, Devineni VR, Janicki JS. Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res. 1995;29:543-548.
6. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
7. van Kleef EM, Smits JF, De Mey JG, Cleutjens JP, Lombardi DM, Schwartz SM, Daemen MJ. Alpha 1-adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery. Circ Res. 1992;70:1122-1127.
8. deBlois D, Schwartz SM, van Kleef EM, Su JE, Griffin KA, Bidani AK, Daemen MJ, Lombardi DM. Chronic alpha 1-adrenoreceptor stimulation increases DNA synthesis in rat arterial wall: modulation of responsiveness after vascular injury. Arterioscler Thromb Vasc Biol. 1996;16: 1122-1129.
9. Yu SM, Tsai SY, Guh JH, Ko FN, Teng CM, Ou JT. Mechanism of catecholamine-induced proliferation of vascular smooth muscle cells. . Circulation. 1996;94:547-554.
10. Kowala MC, Nicolosi RJ. Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report. J Cardiovasc Pharmacol. 1989; 13(suppl 2):S45-S49.
11. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272: 685-688.
12. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111-1115.
13. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
14. Chobanian AV, Hope S, Brecher P. Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1995;25:1306-1310.
15. Chobanian AV, Lichtenstein AH, Nilakhe V, Haudenschild CC, Drago R, Nickerson C. Influence of hypertension on aortic atherosclerosis in the Watanabe rabbit. Hypertension. 1989;14:203-209.
16. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb. 1994;14: 753-759.
17. Krege JH, Moyer JS, Langenbach LL, Peng L, Zhang SH, Maeda N, Reddick RL, Smithies O. Angiotensin-converting enzyme gene and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1245-1250.
18. Chobanian AV. Can antihypertensive drugs reduce atherosclerosis and its clinical complications? Am J Hypertens. 1994;7:119S-125S.
19. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987;84:5928-5931.
20. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, Quarfordt SH, Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest. 1997;99:2858-2866.